Insights

Loading spinner
Gathering insights about Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Tech Stack

Iovance Biotherapeutics, Inc. uses 8 technology products and services including NetSuite, Crowdstrike, Tibco, and more. Explore Iovance Biotherapeutics, Inc.'s tech stack below.

  • NetSuite
    E-commerce
  • Crowdstrike
    Endpoint Protection
  • Tibco
    Enterprise
  • Flickity
    Javascript Libraries
  • Office 365
    Office Suites
  • Windows Server
    Operating Systems
  • VMware
    Virtualisation Software
  • Minitab
    Visualisation Software

Media & News

Iovance Biotherapeutics, Inc.'s Email Address Formats

Iovance Biotherapeutics, Inc. uses at least 2 format(s):
Iovance Biotherapeutics, Inc. Email FormatsExamplePercentage
first.middle@iovance.comJohn.Michael@iovance.com
33%
first.middlelast@iovance.comJohn.MichaelDoe@iovance.com
34%
first.l@iovance.comJohn.D@iovance.com
22%
first.last@iovance.comJohn.Doe@iovance.com
11%
last@lionbio.comDoe@lionbio.com
52%
first.last@lionbio.comJohn.Doe@lionbio.com
41%
first@lionbio.comJohn@lionbio.com
4%
firstmiddle.last@lionbio.comJohnMichael.Doe@lionbio.com
3%

Frequently Asked Questions

Where is Iovance Biotherapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc.'s main headquarters is located at 825 Industrial Rd Suite 400 San Carlos, California 94070 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Iovance Biotherapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Iovance Biotherapeutics, Inc.'s main corporate office by phone at +1-650-260-7120. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Iovance Biotherapeutics, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc. is a publicly traded company; the company's stock symbol is IOVA.

What is Iovance Biotherapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc.'s official website is iovance.com and has social profiles on LinkedIn.

How much revenue does Iovance Biotherapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of May 2024, Iovance Biotherapeutics, Inc.'s annual revenue reached $750M.

What is Iovance Biotherapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Iovance Biotherapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of May 2024, Iovance Biotherapeutics, Inc. has approximately 592 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: J. B.Chief Medical Officer: F. G. F.Chief Financial Officer: B. B.. Explore Iovance Biotherapeutics, Inc.'s employee directory with LeadIQ.

What industry does Iovance Biotherapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Iovance Biotherapeutics, Inc. use?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc.'s tech stack includes NetSuiteCrowdstrikeTibcoFlickityOffice 365Windows ServerVMwareMinitab.

What is Iovance Biotherapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc.'s email format typically follows the pattern of . Find more Iovance Biotherapeutics, Inc. email formats with LeadIQ.

How much funding has Iovance Biotherapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of May 2024, Iovance Biotherapeutics, Inc. has raised $211M in funding. The last funding round occurred on Feb 20, 2024.

When was Iovance Biotherapeutics, Inc. founded?

Minus sign iconPlus sign icon
Iovance Biotherapeutics, Inc. was founded in 2007.
Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

Biotechnology ResearchCalifornia, United States501-1000 Employees

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. 

Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings 

Section iconCompany Overview

Headquarters
825 Industrial Rd Suite 400 San Carlos, California 94070 US
Phone number
+1-650-260-7120
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
IOVA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2007
Employees
501-1000

Section iconFunding & Financials

  • $211M

    Iovance Biotherapeutics, Inc. has raised a total of $211M of funding over 8 rounds. Their latest funding round was raised on Feb 20, 2024.

  • $100M$1B

    Iovance Biotherapeutics, Inc.'s revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $211M

    Iovance Biotherapeutics, Inc. has raised a total of $211M of funding over 8 rounds. Their latest funding round was raised on Feb 20, 2024.

  • $100M$1B

    Iovance Biotherapeutics, Inc.'s revenue is in the range of $100M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.